Human Tissue Kallikrein Activity in Angiographically Documented Chronic Stable Coronary Artery Disease

Estêvão Lanna Figueiredo1, Carolina Antunes Magalhães2, Karlyse Claudino Belli3

  • 1Departamento de Cardiologia, Hospital Lifecenter, Belo Horizonte, MG, Brazil.

Insights

Coronary artery disease (CAD) patients exhibit reduced urinary human tissue kallikrein (hK1) amidase activity, indicating potential impairment in the renal kallikrein-kinin system (KKS). This finding suggests a link between hK1 levels and cardiovascular health.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Human tissue kallikrein (hK1) is a crucial enzyme in the kallikrein-kinin system (KKS).
  • Reduced urinary hK1 amidase activity is observed in patients with hypertension and heart failure (HF).
  • The role of hK1 in coronary artery disease (CAD) pathophysiology is not well understood.

Purpose of the Study:

  • To investigate and quantify urinary hK1-specific amidase activity in patients with and without CAD.
  • To explore the association between hK1 activity and the presence and severity of coronary artery disease.

Main Methods:

  • Sixty-five patients undergoing cardiac catheterism were enrolled.
  • Urine samples were collected pre-catheterization and categorized based on coronary lesion presence (CAD vs. non-CAD).
  • Urinary hK1 amidase activity was measured using a chromogenic substrate and normalized to creatinine levels.

Main Results:

  • Urinary hK1-specific amidase activity was comparable between CAD and non-CAD groups.
  • Activity levels in CAD patients were similar to those previously reported for hypertensive and HF patients.
  • Neither CAD severity nor hypertension significantly influenced urinary hK1 amidase activity.

Conclusions:

  • Patients with CAD demonstrate diminished urinary hK1-specific amidase activity.
  • This suggests a potential reduction in renal KKS activity associated with coronary artery disease.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
770
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
451